ictegratinib
Phase 2
Eli Lillyictegratinib is one of 33 therapeutic programs targeting Autosomal Dominant Polycystic Kidney Disease. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
41 competitors in Autosomal Dominant Polycystic Kidney Disease
#DrugCompanyPhaseTrials
1Samsca
OtsukaApproved
Afinitor
NovartisApproved
Jardiance
Boehringer IngelheimApproved
Lanreotide Acetate
AAlbireo, an Ipsen Company
Approved
Sandostatin
Sun PharmaApproved
Versed
CConrado Roberto Hoffmann Filho
Approved
Lesinurad
EEsperion Therapeutics, Inc.
Approved
Aldactone
PfizerPhase 3
Reata
BiogenPhase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for ictegratinib. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company